Braveheart Bio/$BRVE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Braveheart Bio
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
- Ticker
- $BRVE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 49
- Headquarters
- San Francisco, United States
- Website
- www.braveheart.bio
Braveheart Bio Metrics
BasicAdvanced
$1.7B
-
-$3.58
-
-
Price and volume
Market cap
$1.7B
52-week high
$32.00
52-week low
$16.70
Average daily volume
412K
Financial strength
Current ratio
21.566
Quick ratio
20.948
Long term debt to equity
0
Total debt to equity
0.001
Profitability
Management effectiveness
Valuation
Price to book
3.45
Price to tangible book (TTM)
3.45
Price to free cash flow (TTM)
-7.434
Free cash flow yield (TTM)
-13.45%
Free cash flow per share (TTM)
-2.811
Growth
Bulls say / Bears say
In a placebo-controlled Phase 2 trial in non-obstructive HCM, BHB-1893 improved cardiac biomarkers and heart structure, with gains in symptoms and exercise capacity too. That gives the drug an encouraging early signal in a form of HCM with few treatment options. (Hengrui Pharma)
In a 42-patient obstructive HCM study, 86% of patients in one dose group had a complete gradient response by week 12, and the average gradient fell below the response threshold as early as day five. The rapid effect supports the drug’s potential, although larger controlled trials are needed to confirm it. (SEC)
The IPO lifted pro forma cash to about $527 million, which the company expects to fund its plans into 2029. That gives Braveheart room to run its two Phase 3 programmes without an immediate need to raise more money. (SEC)
The non-obstructive HCM results come from just 84 patients treated for 12 weeks, and the trial’s main goal was safety; efficacy measures were secondary. Phase 3 studies will need to show that the early signals translate into lasting clinical benefit. (Hengrui Pharma)
The non-obstructive HCM trial recorded temporary drops in ejection fraction to 46–49% in four treated patients, requiring dose reductions. While all recovered above 50% after dose adjustment, this remains a safety and monitoring risk to test in larger, longer studies. (Hengrui Pharma)
Braveheart’s prospectus says it has no alternative product candidate if BHB-1893 fails and that larger competitors hold substantial market share and resources. The company therefore has both single-drug risk and a high bar to win uptake if the drug reaches market. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Upcoming events
No upcoming events
Braveheart Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.